| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Quest and Labcorp may be archrivals in the diagnostic testing market, but they appear to agree on at least one thing: the potential demand for quick, at-home testing for women’s sexual health. The lab giants, in separate agreements announced Thursday, Jan. 8, have added Visby Medical’s newly approved, fully at-home PCR test for sexually transmitted infections to their lineup of direct-to-consumer women’s health offerings.
Southfield, Mich.-based Corewell Health and Secaucus, N.J.-based Quest Diagnostics have finalized a lab joint venture and hospital lab management agreement. Quest Diagnostics and Corewell Health’s existing labs will continue to provide services to the joint venture until a 100,000-square-foot centralized lab at the Corewell Health Southfield Center opens in the first quarter of 2027. The new facility will feature advanced diagnostic technologies, including high-throughput molecular testing and automated microbiology.
Quest Diagnostics handles the blood and other biological specimens of one in three Americans every year — and much of the testing, processing and logistics of those samples runs largely unseen through Tampa Bay.
AI, new diagnostics, and shifting care delivery models are among the clinical laboratory predictions for 2026. Cardiometabolic testing is one example, where labs are being asked to look beyond single endpoints. “In 2025, we saw many individuals focus on weight loss as a means of potentially improving their cardiometabolic health,” says Mouris Saghir, PhD, vice president and general manager for cardiometabolic, endocrine, and wellness at Quest Diagnostics.
Lab testing companies including giants Quest Diagnostics and LabCorp are pressing Congress to stop hundreds of millions of dollars of Medicare cuts for diagnostic tests that are due to take effect at the end of January. Their push could add to the health care issues piling up on lawmakers' plates as the calendar flips over. Clinical lab companies say letting the cuts take effect will leave them with less money to spend on creating new diagnostics or technologies to generate quicker results. "Labs play a critical part in trying to keep the nation well — identifying that risk before it ever even happens," said Yuri Fesko, chief medical officer at Quest.
Quest Diagnostics, a cancer treatment laboratory located in Lewisville, was honored by the Lewisville City Council after developing a medical breakthrough that could decrease the risk of diseases returning to treated patients. The laboratory was recognized for its achievement in developing Haystack MRD, a non-invasive, tumor-informed MRD test that searches for tiny tumor fragments in people who have previously or currently have a solid tumor.
In our latest podcast, Elizabeth Marlowe, PhD, D(ABMM), discusses the findings of Quest Diagnostics' large US HIV testing study, which showed a significant decline in HIV drug resistance across major antiretroviral classes, reflecting the impact of modern high-barrier therapies and improved viral suppression.
Even though exercise is good for us, working out can sometimes feel stressful: fitting in time for the gym, making sure we have clean workout clothes, monitoring our daily step count, pushing our runs, rides, and reps to be faster, harder, and just, well, more. If this sounds familiar, you’ll be pleased (and surprised!) to know that the latest fitness trend is all about doing less. If this sounds familiar, you’ll be pleased (and surprised!) to know that the latest fitness trend is all about doing less. In fact, it’s not a traditional workout at all—but it does have some legit benefits for physical health and mental wellbeing. “Getting up and moving around is good for your mental health,” says Marc Penn, M.D., Ph.D., FACC, a senior advisor and medical director of cardio-metabolic endocrine at Quest Diagnostics. Low-intensity activity can improve mood. Plus, clutter can add to stress and mental health issues, so if you’re using your Zone Zero time to tidy up, you get a two-for-one.
To explore what the next year may hold, MLO spoke with 12 laboratory professionals whose roles span bench operations, laboratory quality, enterprise leadership, diagnostics innovation, and health-tech entrepreneurship. Their predictions reflect both optimism and urgency: calls to rebuild the workforce pipeline, integrate multi-site networks, strengthen clinical collaboration, modernize infrastructure, and streamline the process of test result to clinical action. Yuri Fesko, MD, Chief Medical Officer, Quest Diagnostics: "Laboratories across the United States will need to continue being agile and flexible to meet demands from patients, providers, and health systems. That is particularly true in areas like preventive health and wellness, where growth of alternative, consumer-driven models of care will force traditional healthcare providers to be more innovative, dynamic, and user-friendly, allowing patients to interact with this new and growing system closer to home through lab networks like Quest Diagnostics."
Only approximately one-third of US adults diagnosed with hepatitis C virus (HCV) infection received treatment from 2014 to 2021, despite the widespread availability of curative therapies, according to study results published in the Journal of Viral Hepatitis. The US has the fifth highest burden of HCV worldwide. The World Health Organization (WHO) set a goal to eliminate HCV in 2030 by diagnosing at least 90% and treating at least 80% of individuals infected with HCV. Investigators analyzed deidentified data from 2 large commercial laboratories: LabCorp and Quest Diagnostics.
Self-collection for HPV and other infections offers a more convenient, private way to complete recommended screenings—helping reach women who might otherwise delay or skip care. By D. Alagia III, MD, MS, MBA, FACS, FACOG, Quest Diagnostics
Oncologists face a difficult decision after surgically removing a solid tumor. Some patients harbor residual cancer cells, known as minimal residual disease (MRD), and need additional therapy to avoid recurrence, while others are already cured. Determining who falls into each group remains a major challenge in cancer care. “One of the challenges facing ctDNA technologies is, how do we identify ctDNA molecules that are very low abundance in circulation with high accuracy?” said Dan Edelstein, the vice president and general manager of Haystack Oncology at Quest Diagnostics®. Recognizing the need to detect ctDNA reliably, Haystack Oncology developed Haystack MRD®, a next-generation workflow for ultrasensitive residual disease monitoring.
Social media is flooded with ads for at-home blood testing services that promise insights into healthier living, so ABC News' Becky Worley tried one to see what the results really reveal. Becky recieved her blood draw at Quest's patient service center in Oakland, California.
A cancer treatment laboratory in Lewisville made a medical breakthrough that could decrease the risk of the disease returning after a patient has been treated. After somebody has been treated for a cancerous tumor, very small amounts of disease may remain in the body, which traditional tests may miss. Quest Diagnostics, headquartered in Lewisville, has created a new blood test that can identify tiny bits of cancer post-treatment. Currently, Lewisville’s Quest Diagnostics laboratory is the only lab in the country that processes this test for patients and doctors nationwide.
Quest Diagnostics-owned liquid biopsy developer Haystack Oncology is expecting in the next year to bring a new wealth of data supporting the ability of its circulating tumor DNA technology for use in minimal/molecular residual disease (MRD) detection across a variety of indications, especially those where its higher sensitivity may give it a boost over other technologies.
During a talk at the Jefferies Healthcare Services Conference this week, Quest Diagnostics CFO Sam Samad noted developments within several parts of the company's advanced testing business and highlighted blood-based Alzheimer's testing as a particularly strong growth area.
Guardant Health and Quest Diagnostics will collaborate to offer Guardant’s Shield blood-based colorectal cancer test through Quest’s distribution network, the companies said Wednesday. Physicians will be able to order the test through their Quest accounts and electronic health record starting in the first quarter of 2026.
Overall rates of HIV drug resistance declined by nearly 17% between 2018 and 2024, according to a large analysis from Quest Diagnostics published in Open Forum Infectious Diseases. The researchers assessed the prevalence of mutations that confer resistance to nucleoside/nucleotide reverse-transcriptase inhibitors (NRTIs), non-nucleoside reverse-transcriptase inhibitors (NNRTIs), protease inhibitors and integrase inhibitors.
Quest Diagnostics has struck a deal to use healthcare software firm Epic Systems' suite of enterprise laboratory software and services, the companies said on Tuesday. Under the agreement, Epic's enterprise offerings — including its Aura specialty lab data exchange system, its Beaker lab information system, and its MyChart patient health record portal — will be implemented across Quest's national lab operations.
The collaboration will allow wearable device users to order clinical tests, schedule appointments, and receive results through the WHOOP mobile application. WHOOP announced that Quest Diagnostics will serve as the US lab provider for WHOOP Advanced Labs, a new feature that will integrate clinical laboratory testing into the wearable device company’s mobile application.
Quest Diagnostics-owned liquid biopsy developer Haystack Oncology is expecting in the next year to bring a new wealth of data supporting the ability of its circulating tumor DNA technology for use in minimal/molecular residual disease (MRD) detection across a variety of indications, especially those where its higher sensitivity may give it a boost over other technologies.
The relationship between Quest Diagnostics and Hackensack Meridian Health is taking another test. For the last four years, the Secaucus-based lab services provider has managed laboratory operations and performed reference testing for 11 hospitals in the Edison-headquartered health care network. Quest recently deepened that collaboration by opening its 250,000-square-foot next-generation flagship laboratory in Clifton to give students at Hackensack Meridian Health’s School of Medicine a behind-the-scenes look at clinical lab work.
Quest Diagnostics has launched a pharmacogenomic (PGx) laboratory test service designed to help healthcare providers understand individual genetic responses to select drug therapies and optimize medication selection and dosing decisions.
New research by Quest Diagnostics suggests that more and more U.S. workers are using the powerful synthetic opioid drug fentanyl, since it’s showing up in random drug tests carried out in workplaces across the country. This bleak news might not be too surprising, given the dramatic speed with which the drug has affected a population that remains plagued by opioid addiction.
Quest Diagnostics has introduced a new pharmacogenomic (PGx) laboratory testing service designed to assist healthcare providers in understanding their patients’ genetic responses to specific medications. This service is intended to support clinicians in selecting appropriate drugs and determining optimal dosages.